1 / 3

Switch studies in virologically suppressed patients

Switch studies in virologically suppressed patients. Switch to TDF/FTC/EFV AI266-073 Switch to FTC + ddI + EFV ALIZE Switch to ATV/r-containing regimen ATAZIP Switch to ATV ± r-containing regimen SWAN SLOAT Switch to ATV-containing regimen ARIES INDUMA Switch to ATV/r monotherapy

nirav
Download Presentation

Switch studies in virologically suppressed patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Switch studies in virologically suppressed patients Switch to TDF/FTC/EFV AI266-073 Switch to FTC + ddI + EFV ALIZE Switch to ATV/r-containing regimen ATAZIP Switch to ATV±r-containing regimen SWAN SLOAT Switch to ATV-containing regimen ARIES INDUMA Switch to ATV/r monotherapy ATARITMO Swedish Study ACTG A5201 OREY Synopsis • Switch to LPV/r monotherapy • Pilot LPV/r • M03-613 • American Study • KalMo • OK • OK04 • KALESOLO • MOST • HIV-NAT 077 • Switch to DRV/r monotherapy • MONOI • MONET • Switch to RAL-containing regimen • Canadian Study • CHEER • Montreal Study • EASIER • SWITCHMRK • SPIRAL

  2. OREY Study: Switch to ATV/r monotherapy • Design Open-label Single-arm Pilot trial W48 HIV+ No history of prior virologic failure On ATV/r + 2 NRTIs ≥ 8 weeks HIV-1 RNA < 50 c/mL ≥ 24 weeks N = 61 • Primary endpoint • Proportion of patients with virologic rebound (HIV-1 RNA ≥ 400 c/mL)or treatment discontinuation by W48 Pulido F, EACS 2009;Abs. PS4/6 OREY

  3. OREY Study: Switch to ATV/r monotherapy • Mean duration of prior ATV/r therapy: 84 weeks • Use of PI prior to ATV/r: 59% • Median CD4 cell count/mm3 at inclusion: 514 • Outcome at Week 48 • Treatment failure, N = 13: 21% (95% CI: 11.9 -33.7%) • Virologic rebound ≥ 400 c/mL, N = 7: 12% • Virologic rebound ≥ 50 c/ml, N = 16: 27% • Maintenance of HIV-1 RNA suppression < 50 c/mL: 67% • Genotype at virologic rebound > 400 c/ml, N = 7 ; Major PI resistance in 1/7 + 1 post W48 • Grade 3 or 4 total bilirubin: 64% • AE leading to discontinuation, N = 1 • Conclusion • Pilot study of ATV/r monotherapy showing maintenance of virologic suppression in 79% of patients Pulido F, EACS 2009;Abs. PS4/6 OREY

More Related